

Endo International plc
Q3 2016
Financial Results

November 8, 2016



Forward Looking Statements; Non-GAAP Financial Measures

This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future projects” or similar expressions are forward looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward looking statements involve risks and uncertainties. Although Endo believes that these forward looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the United States and Canada including under the caption “Risk Factors” in Endo’s Form 10-K, Form 10-Q and Form 8-K filings, as applicable, with the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis and Retrieval (“SEDAR”) and as otherwise enumerated herein or therein, could affect Endo’s future financial results and could cause Endo’s actual results to differ materially from those expressed in any forward looking statements. The forward looking statements in this presentation are qualified by these risk factors. Endo assumes no obligation to publicly update any forward looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.

This presentation may refer to non-GAAP financial measures, including adjusted diluted EPS and adjusted EBITDA, that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo’s current report on Form 8-K furnished to the SEC for Endo’s reasons for including those non-GAAP financial measures in this presentation. Except as noted on Form 8-K, reconciliation of non-GAAP financial measures to the nearest comparable GAAP amounts have been provided within the appendix at the end of this presentation.

Today's Agenda

- Overview & Q3 2016 Snapshot
- Q3 2016 Business Unit Performance
 - U.S. Branded Pharmaceuticals
 - International Pharmaceuticals
 - U.S. Generic Pharmaceuticals
- Q3 2016 Financial Results
- Strategic Updates
 - 2017 Market Environment
 - Corporate Planning Process


Overview

- Delivered solid top- and adjusted bottom-line Q3 2016 results
 - Performance across all business units in line or ahead of Company expectations
 - Exceeded Q3 guidance
- CEO transition sharpens focus on operational execution
 - Product-by-product portfolio assessment and strategic plan development in progress
- Reaffirming full year 2016 revenue and adjusted diluted EPS guidance

Q3 2016 Snapshot

| Revenue (US \$M) | Q3 2016 | Q3 2015 | Y/Y Growth % |
|--------------------------------------|----------------|----------------|-------------------------|
| U.S. Branded Pharmaceuticals | \$280 | \$305 | (8%) |
| U.S. Generic Pharmaceuticals | \$534 | \$368 | 45% |
| International Pharmaceuticals | \$71 | \$73 | (3%) |
| Total | \$884 | \$746 | 19% |

Q3 2016 Performance: U.S. Branded Pharmaceuticals




Overall segment performance stronger than Company expectations

- XIAFLEX® demand vials solid
 - +7% YoY overall, including +11% YoY growth in Peyronie's disease
 - 2016 expectation continues to be low double-digit revenue growth
- BELBUCA™ launch progressing in a challenging opioid market
- Select products performed better than expected
 - Voltaren® Gel, Lidoderm® and Other Branded

Q3 2016 Performance: International Pharmaceuticals


Reported Revenues in \$ Millions



Overall segment performance in line with Company expectations

- **Paladin**
 - Solid performance across base business
 - Nucynta® launched, XIAFLEX® Canadian rights secured
 - Continuing to manage expected LOE impact
- **Litha & Somar**
 - Underlying revenue^[1] growth is outpacing market growth rates; largely driven by volume
 - Continued to improve adjusted operating margins

Q3 2016 Performance: U.S. Generic Pharmaceuticals




Overall segment performance in line with Company expectations

- Sterile injectables:
 - Vasostrict® continues to grow; \$249 million in revenues through Q3 2016
- New launches / Alt Dosages:
 - Strong performance from Alternative Dosages, especially Lidoderm® AG
 - Launched 15 products YTD
- Q3 Base business declined ~20% sequentially from Q2 2016
 - Decline of ~15% excluding stocking and one-time factors
 - Higher than expected Base decline driven by volume loss and deeper pricing pressure – may continue into 2017

U.S. Generics: FY 2016 Product Launch Expectations

U.S. Generics: Anticipated 2016 Product Launches



- ~20 product launches expected
 - 3 First-to-File products
 - 2 Alternative dosage products
 - 4 Sterile injectable products

● *Already Launched*¹

MARKET VALUE**

● \$0 - \$50M

● \$50M - \$100M

● \$100M - \$500M

● \$500M - \$1B

● >\$1B

H1 2016

H2 2016

2016
Submissions

7 filed

18-20



¹Projections based off of market conditions as of May 2016

* Market value defined by IMS sales for 12 months ended June 30, 2016

U.S. Generics:

Generic SEROQUEL XR® and Zetia® Launches

- Generic SEROQUEL XR® – November 1, 2016
 - Product launched as expected November 1, 2016
 - Under settlement agreement with a supply contract in place
 - Product manufacturing, launch and shipping all on track

- Generic Zetia® - December 12, 2016
 - Have received final approval from FDA
 - Settlement agreement in place with Merck through manufacturing partner Glenmark
 - Product is in our warehouse and ready to launch

Q3 2016 Financial Results



Q3 2016: Financial Results

(Continuing Operations*)

| (US \$M, except EPS) | Q3 2016 | | Q3 2015 | |
|---|----------|----------|----------|-----------------------|
| | GAAP | Non-GAAP | GAAP | Non-GAAP |
| Revenue | \$884 | \$884 | \$746 | \$746 |
| Gross Margin | 37.0% | 63.0% | 40.7% | 63.5% |
| Operating Income (Loss) | (\$36) | \$333 | (\$777) | \$315 |
| (Loss) Income from Continuing Operations | (\$191) | \$226 | (\$804) | \$214 ⁽¹⁾ |
| Effective Tax Rate | (32%) | (1%) | 17% | 1% ⁽¹⁾ |
| Diluted EPS | (\$0.86) | \$1.01 | (\$3.84) | \$1.02 ⁽¹⁾ |
| Weighted Average Diluted Shares Outstanding | 223 | 223 | 209 | 211 |

⁽¹⁾ See FN 12 of the Non-GAAP Reconciliations in Exhibit 99.1 to the 8-K filed November 8, 2016 for the impact of the SEC's recently updated guidance on Non-GAAP measures issued in May 2016

* Continuing Operations includes Endo and Par and excludes ASTORA (formerly known as AMS Women's Health)





2016 Financial Guidance - Updated (Continuing Operations*)

| Measure | FY 2016 Financial Guidance |
|---|----------------------------|
| Revenues | \$3.87B - \$4.03B |
| Adjusted Gross Margin | ~ 60.0% |
| Adjusted Operating Expense to Revenue Ratio | ~ 22.5% |
| Adjusted Interest Expense | ~ \$450M |
| Adjusted Effective Tax Rate | Zero - 2.0% |
| Adjusted Diluted EP | \$4.50 - \$4.80 |
| GAAP EPS | \$0.98 - \$1.28 |
| Weighted Average Diluted Shares Outstanding | ~223M |



* Continuing Operations includes Endo and Par and excludes ASTORA (formerly known as AMS Women's Health)

Liquidity Profile

| (\$M) | Q1 '16 | Q2 '16 | Q3 '16 | YTD '16 |
|--|---------------|--------------|----------------|--------------|
| Reported GAAP Cash Flow provided by / (used in) Operating Activities | \$(50) | \$604 | \$(111) | \$443 |
|  | | | | |
| Certain Cash Items included in Reported Cash Flow from Operations*: | | | | |
| Mesh Liability & Other Litigation | \$214 | \$344 | \$374 | \$932 |
| Transaction Costs & Integration Costs | \$31 | \$18 | \$5 | \$54 |
| Separation & Restructuring Costs | \$20 | \$36 | \$18 | \$74 |
| Federal Tax Refunds Received | - | (\$707) | (\$5) | (\$712) |
|  | | | | |

The above table is not intended to foot; Table may not total due to rounding



* Not all inclusive; pre-tax totals; for more information and full details, please see Endo's Form 10-K/10-Q

Full Year 2016: Projected Free Cash Flow Update

\$ in Millions except EPS

| Full Year 2016 | Low | High |
|---|----------------|----------------|
| Adjusted EPS Guidance Range | \$4.50 | \$4.80 |
| Implied Adjusted EBITDA Range^[1] | \$1,615 | \$1,660 |
| Cash Interest | ~(\$420) | |
| Changes in Working Capital and Other Assets & Liabilities | ~(\$200) | |
| Cash Taxes | ~(\$70) | |
| Milestone/Commercial Payments | ~(\$35) | |
| Restructuring and Integration Related Costs ^[2] | ~(\$160) | |
| Cash Flow – Pre-Mesh and Other Settlements | ~\$730 | ~\$775 |
| Mesh Payments and Related Legal Expenses Net of Tax Refund ^[3] | ~(\$150) | |
| Non-Mesh Settlement Payments ^[4] | ~(\$75) | |
| Cash Flow – Post Mesh and Other Settlements | \$505 | \$550 |
| Capital Expenditures | ~(\$115) | |
| Contingent Consideration and Other | ~(\$90) | |
| Estimated Free Cash Flow | \$300 | \$345 |

^[1] Calculated implied Adjusted EBITDA based on Adjusted EPS guidance range, 223M shares outstanding, 0-2% Adjusted Tax Rate, Interest expense of \$450M, and combined depreciation & stock-based compensation expense of ~\$135M

^[2] Restructuring and integration related costs consist of ~\$70M of integration expenses related primarily to the acquisition of Par Pharmaceuticals, ~\$40M of Severance costs primarily related to Par Pharmaceuticals, and ~\$50M in costs associated with the shutdown of the ASTORA Women's Health

^[3] For presentation purposes "Mesh Payments and Related Legal Expenses Net of Tax Refund" represents total cash outlays related to Mesh, including mesh related legal expense and those outlays that are reflected under Cash Flow From Investing, net of tax refunds of \$759M received in 2016.

^[4] Non-Mesh Settlement Payments represents additional legal settlements that Endo expects to pay in 2016



Strategic Updates



Strategic Updates: 2017 Market Environment

- Generics competitive landscape and pricing pressures
 - Deeper Base business erosion trends indicate headwinds as we enter 2017
 - Increased consortium pricing pressures in and out of formal bid cycles
 - 505b2 expectations and longer-term strategy impacted by competitive landscape, regulatory actions and pricing environment
- XIAFLEX®
 - Core U.S. Branded product
 - Analysis of R&D pipeline and priority programs ongoing
- BELBUCA™
 - Launch of differentiated product is progressing; assessment underway
- Mesh liability
 - Ongoing strategic evaluation and execution

Strategic Updates: Corporate Planning Process

- Reaffirming revenue and adjusted EPS full-year 2016 financial guidance: 2016 business performance continues to be in line with our expectations
- Bottoms-up, product-by-product assessment of all three business units underway
- Full strategic planning process update and corporate strategy rollout expected in February 2017 around Q4 2016 earnings and 2017 guidance announcement

Endo International plc
Q3 2016
Financial Results

November 8, 2016



Appendix



Cash Conversion Cycle ⁽¹⁾

We use days sales outstanding (DSO), days payable outstanding (DPO) and days inventory on hand (DIO), the sum of which is the cash conversion cycle, to evaluate our working capital performance. The following table summarizes the details of the financial metrics used to calculate these working capital performance statistics for the quarters ended September 30, 2016, December 31, 2015 and December 31, 2014 (in thousands, except ratios):

| | September 30, 2016 | December 31, 2015 | December 31, 2014 |
|--|-----------------------|----------------------|----------------------|
| Total revenues | \$ 884,335 | \$ 1,073,697 | \$ 662,877 |
| DSO: | | | |
| Accounts receivable, net of allowance (1) | \$ 669,815 | \$ 995,077 | \$ 1,118,720 |
| Less: Returns and allowances | (343,811) | (356,932) | (174,941) |
| Less: Rebates | — | — | (209,370) |
| Less: Chargebacks | — | — | (206,819) |
| Less: Other sales deductions | — | — | (25,313) |
| Accounts receivable, adjusted for non-cash items | \$ 326,004 | \$ 638,145 | \$ 502,277 |
| Total revenues per day | \$ 9,612 | \$ 11,671 | \$ 7,205 |
| DSO | 34 | 55 | 70 |
| DPO: | | | |
| Accounts payable | \$ 306,096 | \$ 344,267 | \$ 294,001 |
| Plus: Accrued rebates and chargebacks paid in cash | 235,721 | 349,991 | 298,577 |
| Accounts payable, adjusted for rebates | \$ 541,817 | \$ 694,258 | \$ 592,578 |
| Total revenues per day | \$ 9,612 | \$ 11,671 | \$ 7,205 |
| DPO | 56 | 59 | 82 |
| DIO: | | | |
| Inventories, net | \$ 624,302 | \$ 744,665 | \$ 414,995 |
| Plus: Long-term inventory | 32,600 | 24,891 | — |
| Less: Inventory step-up | (10,332) | (117,179) | (22,945) |
| Inventory, adjusted for long-term and non-cash items | \$ 646,570 | \$ 652,377 | \$ 392,050 |
| Total revenues per day | \$ 9,612 | \$ 11,671 | \$ 7,205 |
| DIO | 67 | 56 | 54 |
| Cash conversion cycle | 45 | 52 | 42 |

(1) We have classified certain revenue reserves as reductions from Accounts receivable on our Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015. For additional information on this reclassification, see Note 2. Summary of Significant Accounting Policies in our 2015 Annual Report on Form 10-K.

Reconciliation of Non-GAAP Measures

Three Months Ended September 30, 2016

| | Total revenues | Cost of revenues | Gross margin | Gross margin % | Total operating expenses | Operating expense to revenue % | Operating loss from continuing operations | Operating margin % | Other non- operating expense, net | Loss from continuing operations before income tax | Income tax expense | Effective tax rate | Loss from continuing operations | Discontinued operations, net of tax | Net loss attributable to Endo International plc (14) | Diluted loss per share (15) |
|--|-------------------|---------------------|------------------|----------------------|--------------------------------|--|--|-----------------------|---|---|-----------------------|-----------------------|---------------------------------------|---|--|-----------------------------------|
| Reported (GAAP) | \$884,335 | \$557,472 | \$326,863 | 37% | \$ 362,856 | 41% | \$ (35,993) | (4)% | \$ 109,318 | \$ (145,311) | \$ 46,185 | (32)% | \$ (191,496) | \$ (27,423) | \$ (218,919) | \$ (0.86) |
| Items impacting comparability: | | | | | | | | | | | | | | | | |
| Amortization of intangible assets (1) | — | (211,548) | 211,548 | | — | | 211,548 | | — | 211,548 | — | | 211,548 | — | 211,548 | 0.95 |
| Inventory step-up and other costs savings (2) | — | (14,208) | 14,208 | | — | | 14,208 | | — | 14,208 | — | | 14,208 | — | 14,208 | 0.06 |
| Upfront and milestone-related payments (3) | — | (664) | 664 | | (1,106) | | 1,770 | | — | 1,770 | — | | 1,770 | — | 1,770 | 0.01 |
| Inventory reserve decrease from restructuring (4) | — | 9,041 | (9,041) | | — | | (9,041) | | — | (9,041) | — | | (9,041) | — | (9,041) | (0.04) |
| Separation benefits and other restructuring (5) | — | (12,989) | 12,989 | | (5,834) | | 18,823 | | — | 18,823 | — | | 18,823 | — | 18,823 | 0.08 |
| Charges for litigation and other legal matters (6) | — | — | — | | (18,256) | | 18,256 | | — | 18,256 | — | | 18,256 | — | 18,256 | 0.08 |
| Asset impairment charges (7) | — | — | — | | (93,504) | | 93,504 | | — | 93,504 | — | | 93,504 | — | 93,504 | 0.42 |
| Acquisition-related and integration costs (8) | — | — | — | | (7,907) | | 7,907 | | — | 7,907 | — | | 7,907 | — | 7,907 | 0.04 |
| Fair value of contingent consideration (9) | — | — | — | | (11,569) | | 11,569 | | — | 11,569 | — | | 11,569 | — | 11,569 | 0.05 |
| Other (11) | — | — | — | | — | | — | | (53) | 53 | — | | 53 | — | 53 | — |
| Tax adjustments (12) | — | — | — | | — | | — | | — | — | (48,418) | | 48,418 | — | 48,418 | 0.22 |
| Exclude discontinued operations, net of tax (13) | — | — | — | | — | | — | | — | — | — | | — | 27,423 | 27,423 | — |
| After considering items (non-GAAP) | \$884,335 | \$327,104 | \$557,231 | 63% | \$ 224,680 | 25% | \$ 332,551 | 38% | \$ 109,265 | \$ 223,286 | \$ (2,233) | (1)% | \$ 225,519 | \$ — | \$ 225,519 | \$ 1.01 |

Reconciliation of Non-GAAP Measures

Three Months Ended September 30, 2015

| | Total revenues | Cost of revenues | Gross margin | Gross margin % | Total operating expenses | Operating expense to revenue % | Operating loss from continuing operations | Operating margin % | Other non- operating expense, net | Loss from continuing operations before income tax | Income tax benefit | Effective tax rate | Loss from continuing operations | Discontinued operations, net of tax | Net loss attributable to Endo International plc (14) | Diluted loss per share (15) |
|--|-------------------|---------------------|-------------------|----------------------|--------------------------------|--|--|-----------------------|--|---|--------------------------|-----------------------|---------------------------------------|---|--|--------------------------------------|
| Reported (GAAP) | \$ 745,727 | \$ 442,459 | \$ 303,268 | 41% | \$ 1,080,467 | 145% | \$ (777,199) | (104)% | \$ 187,446 | \$ (964,645) | \$(160,939) | 17% | \$ (803,706) | \$ (246,782) | \$ (1,050,442) | \$ (3.84) |
| Items impacting comparability: | | | | | | | | | | | | | | | | |
| Amortization of intangible assets (1) | — | (121,503) | 121,503 | | — | | 121,503 | | — | 121,503 | — | | 121,503 | — | 121,503 | 0.57 |
| Inventory step-up and other costs savings (2) | — | (42,919) | 42,919 | | — | | 42,919 | | — | 42,919 | — | | 42,919 | — | 42,919 | 0.21 |
| Upfront and milestone-related payments (3) | — | (4,639) | 4,639 | | (4,622) | | 9,261 | | — | 9,261 | — | | 9,261 | — | 9,261 | 0.04 |
| Separation benefits and other restructuring (5) | — | (906) | 906 | | (21,763) | | 22,669 | | — | 22,669 | — | | 22,669 | — | 22,669 | 0.11 |
| Asset impairment charges (7) | — | — | — | | (923,607) | | 923,607 | | — | 923,607 | — | | 923,607 | — | 923,607 | 4.41 |
| Acquisition-related and integration costs (8) | — | — | — | | (52,585) | | 52,585 | | — | 52,585 | — | | 52,585 | — | 52,585 | 0.25 |
| Fair value of contingent consideration (9) | — | — | — | | 80,273 | | (80,273) | | — | (80,273) | — | | (80,273) | — | (80,273) | (0.38) |
| Non-cash and penalty interest charges (10) | — | — | — | | — | | — | | (1,924) | 1,924 | — | | 1,924 | — | 1,924 | 0.01 |
| Other (11) | — | — | — | | — | | — | | (87,089) | 87,089 | — | | 87,089 | — | 87,089 | 0.42 |
| Tax adjustments (12) | — | — | — | | — | | — | | — | — | 163,468 | | (163,468) | — | (163,468) | (0.78) |
| Exclude discontinued operations, net of tax (13) | — | — | — | | — | | — | | — | — | — | | — | 247,362 | 247,362 | — |
| After considering items (non-GAAP) | \$ 745,727 | \$ 272,492 | \$ 473,235 | 63% | \$ 158,163 | 21% | \$ 315,072 | 42% | \$ 98,433 | \$ 216,639 | \$ 2,529 | 1% | \$ 214,110 | \$ 580 | \$ 214,736 | \$ 1.02 |

Reconciliation of Non-GAAP Measures

Notes to the reconciliation of certain line items included in the GAAP Statements of Operations to the Non-GAAP line items are as follows:

- (1) Adjustments for amortization of commercial intangible assets included the following:

| | Three Months Ended September 30, | |
|---|----------------------------------|-------------------|
| | 2016 | 2015 |
| Amortization of intangible assets excluding fair value step-up from contingent consideration | \$ 198,117 | \$ 113,669 |
| Amortization of intangible assets related to fair value step-up from contingent consideration | 13,431 | 7,834 |
| Total | \$ 211,548 | \$ 121,503 |

- (2) Adjustments for inventory step-up and other cost savings included the following:

| | Three Months Ended September 30, | |
|--|----------------------------------|------------------|
| | 2016 | 2015 |
| Fair value step-up of inventory sold | \$ 11,129 | \$ 38,461 |
| Excess manufacturing costs that will be eliminated pursuant to integration plans | 3,079 | 4,458 |
| Total | \$ 14,208 | \$ 42,919 |

- (3) Adjustments for upfront and milestone-related payments to partners included the following:

| | Three Months Ended September 30, | | | |
|------------------------------|----------------------------------|--------------------|------------------|--------------------|
| | 2016 | | 2015 | |
| | Cost of revenues | Operating expenses | Cost of revenues | Operating expenses |
| Sales-based milestones | \$ 664 | \$ — | \$ 4,639 | \$ — |
| Development-based milestones | — | 1,106 | — | 4,622 |
| Total | 664 | 1,106 | 4,639 | 4,622 |

- (4) To exclude decreases of excess inventory reserves of \$(9.0) million recorded during the three months ended September 30, 2016, primarily related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative. This adjustment resulted from the sell-through of certain inventory previously reserved.

- (5) Adjustments for separation benefits and other restructuring included the following:

| | Three Months Ended September 30, | | | |
|--------------------------|----------------------------------|--------------------|------------------|--------------------|
| | 2016 | | 2015 | |
| | Cost of revenues | Operating expenses | Cost of revenues | Operating expenses |
| Separation benefits | \$ 5,564 | \$ 9,234 | \$ 906 | \$ 21,169 |
| Accelerated depreciation | 7,425 | (4,968) | — | 175 |
| Other | — | 1,568 | — | 419 |
| Total | \$ 12,989 | \$ 5,834 | \$ 906 | \$ 21,763 |

- (6) To exclude litigation settlement charges.

- (7) To exclude asset impairment charges. During the three months ended September 30, 2016 and 2015, we recorded impairment charges of \$93.5 million resulting from a charge of \$72.8 million in our U.S. Branded Pharmaceuticals segment relating to our Sumavel® DosePro® product, which resulted from unfavorable formulary changes and a downturn in its performance, and a \$16.2 million charge on a definite-lived intangible asset in our International Pharmaceuticals segment relating to a third quarter 2016 decision not to pursue commercialization of a product in certain international markets. During the three months ended September 30, 2015, we recorded impairment charges of \$923.6 million resulting from a charge of \$680.0 million, representing the difference between the estimated implied fair value of the former UEO reporting unit's goodwill and its respective net book value, and charges of approximately \$242.9 million on certain intangible assets primarily from our U.S. Branded Pharmaceuticals and U.S. Generic Pharmaceuticals segments.

- (8) Adjustments for acquisition and integration items primarily relate to various acquisitions, including Par Pharmaceuticals and Auxilium Pharmaceuticals, and included the following:

| | Three Months Ended September 30, | |
|---|----------------------------------|------------------|
| | 2016 | 2015 |
| Integration costs (primarily third-party consulting fees) | \$ 7,125 | \$ 6,697 |
| Transaction costs | — | 40,877 |
| Transition services | 1,259 | 3,391 |
| Other | (477) | 1,620 |
| Total | \$ 7,907 | \$ 52,585 |

- (9) To exclude the impact of the change in fair value of contingent consideration resulting from certain market conditions impacting the commercial potential of the underlying products.

- (10) To exclude penalty interest charges of \$1,924.

- (11) Adjustments to other included the following:

| | Three Months Ended September 30, | | | |
|--|----------------------------------|------------------------------|--------------------|------------------------------|
| | 2016 | | 2015 | |
| | Operating expenses | Other non-operating expenses | Operating expenses | Other non-operating expenses |
| Costs associated with unused financing commitments | \$ — | \$ — | \$ — | \$ 64,281 |
| Foreign currency impact related to the re-measurement of intercompany debt instruments | — | (114) | — | (5,693) |
| Loss on extinguishment of debt | — | — | — | 40,909 |
| Other miscellaneous | — | 167 | — | (12,408) |
| Total | \$ — | \$ 53 | \$ — | \$ 87,089 |

- (12) Adjusted income taxes are calculated by tax effecting adjusted pre-tax income at the applicable effective tax rate that will be determined by reference to statutory tax rates in the relevant jurisdiction in which the Company operates and includes current and deferred income tax expense commensurate with the non-GAAP measure of profitability.

During the third quarter of 2016, Endo completed a legal entity reorganization of the Generics business. The restructuring resulted in the recording of a deferred tax charge of \$395.1 million in accordance with applicable accounting guidance. Within the third quarter, Endo recorded a net discrete tax expense of \$42.6 million primarily related to the amortization of the aforementioned deferred charge, which was partially offset by a favorable return to provision adjustment resulting from filing U.S. federal income tax returns. In accordance with our adjusted policy, all but a tax benefit of \$4.4 million of the net discrete tax expense has been removed from our adjusted tax expense due to the distortive nature of the deferred charge amortization. The remaining tax benefit of \$4.4 million is associated with the filing of the U.S. federal income tax returns.

Refer to footnote 14 in the Reconciliation of GAAP and Non-GAAP Financial Measures tables for nine months ended September 30, 2016 and 2015 for further discussion of the legal entity reorganization discussed above and our change in policy resulting from the SEC's updated guidance on Non-GAAP measures issued in May 2016.

- (13) To exclude the results of the Astora business reported as discontinued operations, net of tax.

- (14) This amount includes non-controlling interest \$(46) for the three months ended September 30, 2015.

- (15) Calculated as income (loss) from continuing operations divided by the applicable weighted average share number. The applicable weighted average share number for the three months ended September 30, 2016 is 222,767 and 223,139 for the GAAP and non-GAAP EPS calculations, respectively. The applicable weighted average share number for the three months ended September 30, 2015 is 209,274 for the GAAP EPS calculation and 210,787 for the non-GAAP EPS calculations, respectively.

Reconciliation of Non-GAAP Measures

Nine Months Ended September 30, 2016

| | Total revenues | Cost of revenues | Gross margin | Gross margin % | Total operating expenses | Operating expense to revenue % | Operating loss from continuing operations | Operating margin % | Other non- operating expense, net | Loss from continuing operations before income tax | Income tax benefit | Effective tax rate | Income from continuing operations | Discontinued operations, net of tax | Net loss attributable to Endo International plc (16) | Diluted earnings per share (17) |
|--|--------------------|---------------------|--------------------|----------------------|--------------------------------|--|--|-----------------------|---|--|--------------------------|-----------------------|--|---|--|--|
| Reported (GAAP) | \$2,768,761 | \$1,878,395 | \$ 890,366 | 32% | \$1,067,322 | 39% | \$ (176,956) | (6)% | \$ 341,298 | \$ (518,254) | \$(627,807) | 121% | \$ 109,553 | \$ (118,747) | \$ (9,210) | \$ 0.49 |
| Items impacting comparability: | | | | | | | | | | | | | | | | |
| Amortization of intangible assets (1) | — | (636,061) | 636,061 | | — | | 636,061 | | — | 636,061 | — | | 636,061 | — | 636,061 | 2.84 |
| Inventory step-up and other costs savings (2) | — | (110,437) | 110,437 | | (1,350) | | 111,787 | | — | 111,787 | — | | 111,787 | — | 111,787 | 0.50 |
| Upfront and milestone-related payments (3) | — | (1,973) | 1,973 | | (3,902) | | 5,875 | | — | 5,875 | — | | 5,875 | — | 5,875 | 0.03 |
| Inventory reserve increase from restructuring (4) | — | (24,592) | 24,592 | | — | | 24,592 | | — | 24,592 | — | | 24,592 | — | 24,592 | 0.11 |
| Royalty obligations (5) | — | 7,750 | (7,750) | | — | | (7,750) | | — | (7,750) | — | | (7,750) | — | (7,750) | (0.03) |
| Separation benefits and other restructuring (6) | — | (19,394) | 19,394 | | (26,426) | | 45,820 | | — | 45,820 | — | | 45,820 | — | 45,820 | 0.21 |
| Charges for litigation and other legal matters (8) | — | — | — | | (28,715) | | 28,715 | | — | 28,715 | — | | 28,715 | — | 28,715 | 0.13 |
| Asset impairment charges (9) | — | — | — | | (263,080) | | 263,080 | | — | 263,080 | — | | 263,080 | — | 263,080 | 1.18 |
| Acquisition-related and integration costs (10) | — | — | — | | (55,422) | | 55,422 | | — | 55,422 | — | | 55,422 | — | 55,422 | 0.25 |
| Fair value of contingent consideration (11) | — | — | — | | (24,779) | | 24,779 | | — | 24,779 | — | | 24,779 | — | 24,779 | 0.11 |
| Non-cash and penalty interest charges (12) | — | — | — | | — | | — | | (4,092) | 4,092 | — | | 4,092 | — | 4,092 | 0.02 |
| Other (13) | — | — | — | | — | | — | | 5,437 | (5,437) | — | | (5,437) | — | (5,437) | (0.02) |
| Tax adjustments (14) | — | — | — | | — | | — | | — | — | 637,998 | | (637,998) | — | (637,998) | (2.87) |
| Exclude discontinued operations, net of tax (15) | — | — | — | | — | | — | | — | — | — | | — | 118,747 | 118,747 | — |
| After considering items (non-GAAP) | \$2,768,761 | \$1,093,688 | \$1,675,073 | 60 % | \$ 663,648 | 24 % | \$ 1,011,425 | 37 % | \$ 342,643 | \$ 668,782 | \$ 10,191 | 2 % | \$ 658,591 | \$ — | \$ 658,575 | \$ 2.95 |

Reconciliation of Non-GAAP Measures

Nine Months Ended September 30, 2015

| | Total revenues | Cost of revenues | Gross margin | Gross margin % | Total operating expenses | Operating expense to revenue % | Operating loss from continuing operations | Operating margin % | Other non- operating expense, net | Loss from continuing operations before income tax | Income tax benefit | Effective tax rate | Loss from continuing operations | Discontinued operations, net of tax | Net loss attributable to Endo International plc (16) | Diluted loss per share (17) |
|---|--------------------|---------------------|--------------------|----------------------|--------------------------------|--|--|-----------------------|---|---|--------------------------|-----------------------|---------------------------------------|---|--|---|
| Reported (GAAP) | \$2,195,021 | \$1,265,583 | \$ 929,438 | 42% | \$1,659,400 | 76% | \$ (729,962) | (33)% | \$ 354,674 | \$ (1,084,636) | \$ (340,528) | 31% | \$ (744,108) | \$ (632,624) | \$ (1,376,579) | \$ (3.96) |
| Items impacting comparability: | | | | | | | | | | | | | | | | |
| Amortization of intangible assets (1) | — | (333,759) | 333,759 | | — | | 333,759 | | — | 333,759 | — | | 333,759 | — | 333,759 | 1.76 |
| Inventory step-up and other costs savings (2) | — | (131,783) | 131,783 | | — | | 131,783 | | — | 131,783 | — | | 131,783 | — | 131,783 | 0.69 |
| Upfront and milestone-related payments (3) | — | (5,866) | 5,866 | | (8,197) | | 14,063 | | — | 14,063 | — | | 14,063 | — | 14,063 | 0.07 |
| Separation benefits and other restructuring (6) | — | (906) | 906 | | (69,350) | | 70,256 | | — | 70,256 | — | | 70,256 | — | 70,256 | 0.36 |
| Acceleration of Auxilium employee equity awards (7) | — | — | — | | (37,603) | | 37,603 | | — | 37,603 | — | | 37,603 | — | 37,603 | 0.20 |
| Charges for litigation and other legal matters (8) | — | — | — | | (19,875) | | 19,875 | | — | 19,875 | — | | 19,875 | — | 19,875 | 0.11 |
| Asset impairment charges (9) | — | — | — | | (1,000,850) | | 1,000,850 | | — | 1,000,850 | — | | 1,000,850 | — | 1,000,850 | 5.31 |
| Acquisition-related and integration costs (10) | — | — | — | | (134,778) | | 134,778 | | — | 134,778 | — | | 134,778 | — | 134,778 | 0.71 |
| Fair value of contingent consideration (11) | — | — | — | | 83,601 | | (83,601) | | — | (83,601) | — | | (83,601) | — | (83,601) | (0.44) |
| Non-cash and penalty interest charges (12) | — | — | — | | — | | — | | (6,302) | 6,302 | — | | 6,302 | — | 6,302 | 0.02 |
| Other (13) | — | — | — | | (800) | | 800 | | (101,864) | 102,664 | — | | 102,664 | — | 102,664 | 0.55 |
| Tax adjustments (14) | — | — | — | | — | | — | | — | — | 398,419 | | (398,419) | — | (398,419) | (2.12) |
| Exclude discontinued operations, net of tax (15) | — | — | — | | — | | — | | — | — | — | | — | 675,998 | 675,998 | — |
| After considering items (non-GAAP) | \$2,195,021 | \$ 793,269 | \$1,401,752 | 64% | \$ 471,548 | 21% | \$ 930,204 | 42% | \$ 246,508 | \$ 683,696 | \$ 57,891 | 8% | \$ 625,805 | \$ 43,374 | \$ 669,332 | \$ 3.26 |

Reconciliation of Non-GAAP Measures

Notes to the reconciliation of certain line items included in the GAAP Statements of Operations to the Non-GAAP line items are as follows:

- (1) Adjustments for amortization of commercial intangible assets included the following:

| | Nine Months Ended September 30, | |
|---|---------------------------------|-------------------|
| | 2016 | 2015 |
| Amortization of intangible assets excluding fair value step-up from contingent consideration | \$ 606,090 | \$ 314,179 |
| Amortization of intangible assets related to fair value step-up from contingent consideration | 29,971 | 19,580 |
| Total | \$ 636,061 | \$ 333,759 |

- (2) Adjustments for inventory step-up and other cost savings included the following:

| | Nine Months Ended September 30, | | | |
|--|---------------------------------|--------------------|-------------------|--------------------|
| | 2016 | | 2015 | |
| | Cost of revenues | Operating expenses | Cost of revenues | Operating expenses |
| Fair value step-up of inventory sold | \$ 99,099 | \$ 957 | \$ 122,714 | \$ — |
| Excess manufacturing costs that will be eliminated pursuant to integration plans | 11,338 | 393 | 9,069 | — |
| Total | \$ 110,437 | \$ 1,350 | \$ 131,783 | \$ — |

- (3) Adjustments for upfront and milestone-related payments to partners included the following:

| | Nine Months Ended September 30, | | | |
|------------------------------|---------------------------------|--------------------|------------------|--------------------|
| | 2016 | | 2015 | |
| | Cost of revenues | Operating expenses | Cost of revenues | Operating expenses |
| Sales-based milestones | \$ 1,973 | \$ — | \$ 5,866 | \$ — |
| Development-based milestones | — | 3,902 | — | 8,197 |
| Total | \$ 1,973 | \$ 3,902 | \$ 5,866 | \$ 8,197 |

- (4) To exclude charges due to increases of excess inventory reserves related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative.

- (5) To adjust for the reversal of the remaining Voltaren® Gel minimum royalty obligations as a result of a generic entrant.

- (6) Adjustments for separation benefits and other restructuring included the following:

| | Nine Months Ended September 30, | | | |
|--|---------------------------------|--------------------|------------------|--------------------|
| | 2016 | | 2015 | |
| | Cost of revenues | Operating expenses | Cost of revenues | Operating expenses |
| Separation benefits | \$ 11,969 | \$ 18,008 | \$ 906 | \$ 58,348 |
| Accelerated depreciation and product discontinuation charges | 7,425 | 2,803 | — | 8,320 |
| Other | — | 5,615 | — | 2,682 |
| Total | \$ 19,394 | \$ 26,426 | \$ 906 | \$ 69,350 |

- (7) To exclude the acceleration of Auxilium employee equity awards at closing of acquisition.

- (8) To exclude litigation settlement charges.

- (9) To exclude asset impairment charges. During the nine months ended September 30, 2016 we recorded pre-tax, non-cash impairment charges of \$263.1 million as a result of a charge of \$72.8 million in our U.S. Branded Pharmaceuticals segment relating to our Sumavel® DopaPro® product, which resulted from unfavorable formulary changes and a downturn in its performance, a \$16.2 million charge on a definite-lived intangible asset in our International Pharmaceuticals segment relating to a third quarter 2016 decision not to pursue commercialization of a product in certain international markets, a \$69.0 million charge due to certain market conditions impacting the commercial potential of certain intangible assets in our U.S. Generic Pharmaceuticals segment, a \$100.3 million charge related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative, which resulted from the discontinuation of certain commercial products and the abandonment of certain IPR&D projects. During the nine months ended September 30, 2015, we recorded pre-tax, non-cash impairment charges of \$1.0 billion as a result of a third quarter 2015 provisional impairment charge of \$680.0 million, representing the difference between the estimated implied fair value of the former UEO reporting unit's goodwill and its respective net book value, \$313.1 million on certain intangible assets primarily from our U.S. Branded Pharmaceuticals and U.S. Generic Pharmaceuticals segments, and \$7.0 million on certain leasehold improvements associated with Auxilium's former headquarters.

- (10) Adjustments for acquisition and integration items primarily relate to various acquisitions, including Par Pharmaceuticals and Auxilium Pharmaceuticals, and included the following:

| | Nine Months Ended September 30, | |
|---|---------------------------------|-------------------|
| | 2016 | 2015 |
| Integration costs (primarily third-party consulting fees) | \$ 38,311 | \$ 23,356 |
| Transaction costs | — | 90,583 |
| Transition services | 9,729 | 12,911 |
| Other | 7,382 | 7,928 |
| Total | \$ 55,422 | \$ 134,778 |

- (11) To exclude the impact of the change in fair value of contingent consideration resulting from certain market conditions impacting the commercial potential of the underlying products.

- (12) Adjustments to interest charges included the following:

| | Nine Months Ended September 30, | |
|--|---------------------------------|-----------------|
| | 2016 | 2015 |
| Penalty interest charges | \$ 4,092 | \$ 4,670 |
| Non-cash interest expense related to our 1.75% Convertible Senior Subordinated Notes | — | 1,632 |
| Total | \$ 4,092 | \$ 6,302 |

- (13) Adjustments to other included the following:

| | Nine Months Ended September 30, | | | |
|--|---------------------------------|------------------------------|--------------------|------------------------------|
| | 2016 | | 2015 | |
| | Operating expenses | Other non-operating expenses | Operating expenses | Other non-operating expenses |
| Costs associated with unused financing commitments | \$ — | \$ — | \$ 800 | \$ 78,352 |
| Other than temporary impairment of equity investment | — | — | — | 18,869 |
| Foreign currency impact related to the re-measurement of intercompany debt instruments | — | 1,558 | — | (23,991) |
| Loss on extinguishment of debt | — | — | — | 41,889 |
| Other miscellaneous expense (income) | — | (6,995) | — | (13,255) |
| Total | \$ — | \$ (5,437) | \$ 800 | \$ 101,864 |

- (14) During the third quarter of 2016, Endo completed a legal entity reorganization that moved the Generics business to a new U.S. holding company structure that is separate from the legacy Branded business structure. The reorganization also provides operating flexibility and benefits and reduces the potential impact related to any future limits that could apply to the use of tax attributes by utilizing most of the Company's attributes to offset the gain in the intercompany sale that stepped-up the tax basis of the U.S. Generics business assets. The utilization of acquired attributes in the reorganization would have had an unfavorable impact of \$157 million on our full-year 2016 adjusted tax expense under Endo's non-GAAP policy prior to the adoption of the SEC's updated guidance on Non-GAAP measures (see below). The elimination of this acquired attribute benefit was largely offset by an improved mix of jurisdictional adjusted pre-tax income resulting primarily from the reorganization. The reorganization also gave rise to a discrete GAAP tax benefit of \$63.5 million arising from outside basis differences. This benefit has been excluded from our adjusted effective tax rate in accordance with our policy.

Separately, as a result of the SEC's updated guidance on Non-GAAP measures issued in May 2016, Endo is no longer excluding the non-cash deferred tax expense associated with acquired attributes in our adjusted income tax expense. This change has no impact on Endo's historic or forward looking GAAP tax or cash tax profile. Additionally, as we have utilized substantially all of our acquired attributes through the recent legal entity reorganization, our change in policy is not expected to have a material impact on our 2016 and forward looking adjusted tax rate. The following table presents the impact of our change in policy on Adjusted Diluted EPS from Continuing Operations for each relevant period of 2015 and 2016:

| | Three Months Ended March 31, 2015 | Three Months Ended June 30, 2015 | Three Months Ended September 30, 2015 | Nine Months Ended September 30, 2015 | Three Months Ended December 31, 2015 | Twelve Months Ended December 31, 2015 | Three Months Ended March 31, 2016 |
|--|-----------------------------------|----------------------------------|---------------------------------------|--------------------------------------|--------------------------------------|---------------------------------------|-----------------------------------|
| Adjusted Diluted EPS from Continuing Operations - As Previously Reported | 1.17 | 1.08 | 1.02 | 3.26 | 1.36 | 4.66 | 1.08 |
| Amount attributable to the change in approach to Non-GAAP income taxes | (0.11) | (0.09) | (0.16) | (0.36) | (0.18) | (0.56) | (0.16) |
| Adjusted Diluted EPS from Continuing Operations - As Revised | 1.06 | 0.99 | 0.86 | 2.90 | 1.18 | 4.10 | 0.92 |

* Amounts in the table above may not add due to rounding

- (15) To exclude the results of the Astora business reported as discontinued operations, net of tax.

- (16) This amount includes noncontrolling interests of \$16 and \$(153) for the nine months ended September 30, 2016 and 2015, respectively.

- (17) Calculated as income (loss) from continuing operations divided by the applicable weighted average share number. The applicable weighted average share number for the nine months ended September 30, 2016 is 223,060 for both the GAAP and non-GAAP EPS calculations. The applicable weighted average share number for the nine months ended September 30, 2015 is 188,085 and 192,144 for the GAAP and non-GAAP EPS calculations, respectively.

Endo International plc
Q3 2016
Financial Results

November 8, 2016

